ÂÜÀòÂÒÂ×

Kyle Roskamp is an accomplished scientist with extensive experience in biochemical research and protein analysis. Currently serving as a Scientist II at PTC Therapeutics, Inc. since August 2022, Kyle previously held the same title at Second Genome Inc., where leadership in mechanism of action studies was demonstrated through the application of structural modeling and various assays. Kyle's earlier roles include impactful research at UC Irvine as a Graduate Student Researcher focused on protein mutations and stability, as well as contributing to the Monarch Initiative at Berkeley Lab. With a strong academic background, including a PhD in Chemistry from UC Irvine and a BA in Chemistry and Mathematics from Pomona College, Kyle has developed significant expertise in protein engineering and bioinformatics throughout the career.